Abstract
Neuroendocrine tumors (NETs) are rare, heterogeneous, indolent tumors that are relatively insensitive to systemic chemotherapy. Therapeutic strategies for NETs broadly include somatostatin analogs, antiangiogenic therapy, and most recently, mammalian target of rapamycin inhibition. Combination therapy has shown promising antitumor activity and good tolerability in the randomized phase III trials. The aim was to evaluate the safety and efficacy of Everolimus plus Octreotide long-acting repeatable (LAR) in patients with advanced NETs in the routine tertiary cancer care setting in India in this postapproval, noninterventional trial. Patients presenting to selected centers between 2011 and 2013 with histologically confirmed low-, intermediate- or high-grade advanced NETs who may have had prior exposure to cytotoxic chemotherapy (≤2 lines) were treated with oral Everolimus (10 mg/day) plus intramuscular Octreotide LAR (30 mg once every 28 days) until disease progression or unacceptable toxicity was seen. Patients were evaluated every 3 months for a response to therapy as per Response Evaluation Criteria in Solid Tumors. Everolimus plus Octreotide LAR was associated with a clinical benefit rate of 69% (best evaluable responses: Stabl...Continue Reading
References
Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Oct 29, 2005·Best Practice & Research. Clinical Gastroenterology·Kjell Oberg, Barbro Eriksson
Dec 3, 2005·Endocrine-related Cancer·Francesco PanzutoGianfranco Delle Fave
Dec 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PanzutoG Delle Fave
Oct 21, 2006·Cancer·Emilio BajettaLeonardo Ferrari
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoJaffer A Ajani
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja RinkeUNKNOWN PROMID Study Group
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoBertram Wiedenmann
Jun 24, 2010·World Journal of Gastroenterology : WJG·Jonathan Strosberg, Larry Kvols
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 12, 2011·Cancer Metastasis Reviews·Kjell Oberg, Daniel Castellano
Nov 29, 2011·Lancet·Marianne E PavelUNKNOWN RADIANT-2 Study Group
Jan 18, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Samer EzziddinAmir Sabet